[클리니컬히스토리] 론자 택한 이뮨온시아, 자체 신약 글로벌 허가 채비

ImmuneOncia's partnership with Lonza for IMC-001 secures a high-standard global production base essential for FDA and EMA regulatory approvals. By leveraging Lonza’s integrated DS and DP manufacturing, the company effectively bridges the gap between clinical success and global commercialization. This collaboration highlights the growing importance of top-tier CDMO partnerships in accelerating the international market entry of domestic biotech pipelines.